Repligen falls as investors refocus on 2026 guidance and gene-therapy headwind
Repligen shares slid as investors continued to digest the company’s Feb. 24, 2026 outlook, which flagged a “two-point” gene therapy headwind baked into 2026 revenue growth expectations. The stock’s drop also follows recent analyst target trims after the guidance update.
1) What’s moving the stock
Repligen (RGEN) is trading lower as the market revisits the company’s 2026 setup outlined with its fourth-quarter report on February 24, 2026, when management guided to $810 million–$840 million in 2026 revenue and highlighted that the outlook includes a two-point gene therapy headwind. That reminder has weighed on sentiment, particularly as investors try to gauge the pace of recovery across bioprocessing demand and how quickly gene therapy-related softness fades. (investors.repligen.com)
2) The key numbers investors are anchoring to
Alongside the 2026 revenue range, Repligen guided to adjusted diluted EPS of $1.93–$2.01 and called for adjusted operating-margin expansion of about 150 basis points at the midpoint. Even with solid Q4 execution, the inclusion of a gene-therapy headwind in the initial 2026 guide has become a focal point for near-term expectations. (investors.repligen.com)
3) Analyst backdrop
Adding to the pressure, recent research actions have skewed cautious: a late-February note cited a downgrade to “hold,” and another prominent update in the same window referenced a reduced price target while maintaining coverage. Those resets can amplify down days when the stock is already in a post-guidance digestion phase. (defenseworld.net)